{"task_id": "859696bd3ef5763d", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 270/464)", "text": "ne or clindamycin\nHuman Immunodeficiency Virus\n259\n\n--- Page 281 ---\nCHRONIC MENINGITIS IN HIV PATIENTS\nDIFFERENTIAL DIAGNOSIS\n\u0002\nCRYPTOCOCCUS (CD4 <100/mm3)\nubiquitous fun\ngus. High opening pressure (>200 cmH2O)\n\u0002\nBACTERIAL MENINGITIS (any CD4)\nN. meningitis, S.\npneumoniae, Listeria, Gram negative bacilli\n\u0002\nVIRAL MENINGITIS (any CD4)\nHSV encephalitis\nDIAGNOSIS\nCBCD, lytes, urea, Cr, blood C&S, serum\nCRAG (sens 95% for Cryptococcus), CT head, lumbar\npuncture (for Cryptococcus and cryptoantigen)\nTREATMENT OF CRYPTOCOCCUS\ninduction with\namphotericin B 0.7 mg/kg IV daily plus flucytosine\n25 mg/kg PO QID, switch to fluconazole 400 mg PO\ndaily \u00052 months for consolidation, followed by\nfluconazole 200 mg PO daily as maintenance. Man\nagement of increased intracranial pressure may be\nneeded\nRESPIRATORY INFECTIONS IN HIV PATIENTS\nDIFFERENTIAL DIAGNOSIS\n\u0002\nCOMMUNITY-ACQUIRED PNEUMONIA (any CD4)\nmost\ncommon cause is S. pneumoniae. Others include\nMoraxella, H. influenzae\n\u0002\nTUBERCULOSIS (any CD4)\n170\u0005 increased risk in\nHIV patients. May be extrapulmonary\n\u0002\nNON-TB MYCOBACTERIUM\nMAC (CD4 <100/mm3,\npulmonary involvement alone is rare, usually\ndisseminated)\n\u0002\nFUNGAL (CD4 <500/mm3)\nHistoplasma, Cocci\ndioides, Cryptococcus\n\u0002\nPNEUMOCYSTIS JIROVECII PNEUMONIA (PJP, CD4 <200/\nmm3)\nDIAGNOSIS\nCBCD, lytes, urea, Cr, LDH (\" in PJP but\nnon specific), blood C&S and mycobacterial culture,\nsputum C&S and AFB, ABG, urine C&S, CXR, broncho\nscopy (lavage, biopsy)\nTREATMENT OF PJP\ntrimethoprim sulfamethoxa\nzole 15 mg of TMP/kg PO/IV divided q8h daily\n\u000521 days. If severe disease (PaO2 <70 mmHg), add\nprednisone 40 mg PO BID \u00055 days, then 40 mg PO\ndaily \u00055 days, then 20 mg PO daily \u000511 days. Alter\nnatives to trimethoprim sulfamethoxazole include\ndapsone plus trimethoprim, or clindamycin plus pri\nmaquine, pentamidine IV. Use atovaquone if G6PD\ndeficiency\nESOPHAGITIS IN HIV PATIENTS\nDIFFERENTIAL DIAGNOSIS\n\u0002\nINFECTIONS\n\u0002\nCANDIDA (CD4 <500/mm3)\n50 70%\n\u0002 HSV (any CD4)\n5 10%\n\u0002 CMV (CD4 <100/mm3)\n5 15%\n\u0002\nNON-INFECTIOUS\nGERD, pill esophagitis, neoplasms\n\u0002\nIDIOPATHIC (any CD4)\n10 30%\nDIAGNOSIS\nempiric therapy (fluconazole), endo\nscopy with cultures for fungus, virus, and biopsy\nHEPATITIS/CHOLANGITIS/PANCREATITIS IN HIV\nPATIENTS\nDIFFERENTIAL DIAGNOSIS\n\u0002\nINFECTIONS\n\u0002 TB (any CD4)\n\u0002\nMYCOBACTERIUM\nAVIUM\nCOMPLEX (MAC, CD4\n<100/mm3)\nM. avium, M. intracellulare\n\u0002\nVIRUSES\nHBV, HCV, CMV\n\u0002\nPARASITES\nCryptosporidium, Microsporidium,\nCyclospora\n\u0002\nALCOHOL\n\u0002\nDRUGS\nantiretrovirals, antibiotics (sulfa, isoniazid,\nrifampin, ketoconazole, fluconazole)\nDIAGNOSIS\nCBCD, lytes, urea, Cr, AST, ALT, ALP,\nbilirubin, lipase, INR, cultures and serologies, U/S\nabd, CT abd, ERCP\nCOLITIS/DIARRHEA IN HIV PATIENTS\nDIFFERENTIAL DIAGNOSIS\n\u0002\nINFECTIONS\n\u0002\nBACTERIAL\nSalmonella, Shigella, Campylobac\nter, Yersinia, EHEC, EIEC, C. difficile\n\u0002 TB (any CD4)\n\u0002\nMYCOBACTERIUM\nAVIUM\nCOMPLEX (MAC, CD4\n<100/mm3)\nM. avium, M. intracellulare\n\u0002 CMV (CD4 <100/mm3)\n\u0002\nPARASITIC wMAGICw\nMicrosporidium, EntA\nmoeba, Giardia, Isospora, Cryptosporidium\n\u0002\nMEDICATIONS\nantiretrovirals, antibiotics\n\u0002 AIDS ENTEROPATHY\ndiagnosis of exclusion\nDIAGNOSIS\nCBCD, lytes, urea, Cr, stool C&S, stool\nO&P with acid fast staining, stool MAC, C. diff toxin,\nfecal WBC, Cryptosporidium\nTREATMENT OF MAC\nclarithromycin 500 mg PO\nBID or azithromycin 600 mg PO daily, plus ethambutol\n15 mg/kg PO daily, plus rifabutin 600 mg PO daily for\nat least 12 months and at least 6 months of immune\nreconstitution (CD4 >100 200/mm3)\nAIDS ASSOCIATED MALIGNANCIES\nAIDS DEFINING MALIGNANCIES\n\u0002 KAPOSI\u2019S\nSARCOMA (any CD4)\nstrongly asso\nciated with HHV8. Lesions may involve skin, oral\nmucosa, lungs, and GI tract. Treat with liposomal\ndoxorubicin\n\u0002\nNON-HODGKIN\u2019S LYMPHOMA (CD4 <100/mm3)\ndif\nfuse large B cell lymphoma, primary effusion lym\nphoma (associated with HHV8 and EBV), and plas\nmablastic lymphomas. Treat with combination\nchemotherapy (CHOPR)\n\u0002\nPRIMARYCNSLYMPHOMA(CD4<100/mm3)\nstrongly\nassociatedwithEBV.Treatwithradiationand/orhigh\ndose methotrexate or intrathecal chemotherapy\n\u0002\nCERVICAL\nCARCINOMA (any CD4)\nstrongly asso\nciated with HPV. Treat with surgery, radiation,\nand/or chemotherapy (cisplatin)\n260\nHuman Immunodeficiency Virus", "text_length": 4160, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 270/464)", "type": "chunk", "chunk_index": 269, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.618178", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.619090", "status": "complete", "chunks_added": 3}